Switch theme
Sign up to access all valuation multiples
Arctic Bioscience AS is a clinical-stage biotechnology company working to develop drug candidates within the areas of autoimmune and inflammatory diseases. It is developing pharmaceutical and commercializing nutraceutical products based on bioactive marine compounds, including lipids essential to maintaining cell membranes. The company’s proprietary extraction technology is used to extract membrane fats from marine raw materials, such as herring roe and algae. The company is developing a novel, oral drug candidate (HRO350) for the treatment of mild-to-moderate psoriasis. The company operates geographically in Norway, Americas, Europe, and APAC, with majority of the revenue deriving from Europe.
2011
25
LTM Revenue $6.2M
LTM EBITDA -$1.9M
$12.8M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Arctic Bioscience has a last 12-month revenue (LTM) of $6.2M and a last 12-month EBITDA of -$1.9M.
In the most recent fiscal year, Arctic Bioscience achieved revenue of $4.3M and an EBITDA of -$3.9M.
Arctic Bioscience expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Arctic Bioscience valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $6.2M | XXX | $4.3M | XXX | XXX | XXX |
| Gross Profit | $3.2M | XXX | $1.2M | XXX | XXX | XXX |
| Gross Margin | 52% | XXX | 27% | XXX | XXX | XXX |
| EBITDA | -$1.9M | XXX | -$3.9M | XXX | XXX | XXX |
| EBITDA Margin | -30% | XXX | -91% | XXX | XXX | XXX |
| EBIT | -$2.7M | XXX | -$4.7M | XXX | XXX | XXX |
| EBIT Margin | -43% | XXX | -110% | XXX | XXX | XXX |
| Net Profit | -$4.8M | XXX | -$4.8M | XXX | XXX | XXX |
| Net Margin | -78% | XXX | -110% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $2.9M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 16, 2025, Arctic Bioscience's stock price is NOK 4 (or $0).
Arctic Bioscience has current market cap of NOK 98.6M (or $9.8M), and EV of NOK 129M (or $12.8M).
See Arctic Bioscience trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $12.8M | $9.8M | XXX | XXX | XXX | XXX | $-0.14 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 16, 2025, Arctic Bioscience has market cap of $9.8M and EV of $12.8M.
Arctic Bioscience's trades at 3.0x EV/Revenue multiple, and -3.3x EV/EBITDA.
Equity research analysts estimate Arctic Bioscience's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Arctic Bioscience has a P/E ratio of -2.0x.
See valuation multiples for Arctic Bioscience and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $9.8M | XXX | $9.8M | XXX | XXX | XXX |
| EV (current) | $12.8M | XXX | $12.8M | XXX | XXX | XXX |
| EV/Revenue | 2.1x | XXX | 3.0x | XXX | XXX | XXX |
| EV/EBITDA | -6.8x | XXX | -3.3x | XXX | XXX | XXX |
| EV/EBIT | -4.8x | XXX | -2.7x | XXX | XXX | XXX |
| EV/Gross Profit | 4.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | -2.0x | XXX | -2.1x | XXX | XXX | XXX |
| EV/FCF | -2.4x | XXX | -1.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialArctic Bioscience's last 12 month revenue growth is 40%
Arctic Bioscience's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.2M for the same period.
Arctic Bioscience's rule of 40 is -76% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Arctic Bioscience's rule of X is 70% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Arctic Bioscience and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 40% | XXX | 48% | XXX | XXX | XXX |
| EBITDA Margin | -30% | XXX | -91% | XXX | XXX | XXX |
| EBITDA Growth | -91% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -76% | XXX | -51% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 70% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 137% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Arctic Bioscience acquired XXX companies to date.
Last acquisition by Arctic Bioscience was XXXXXXXX, XXXXX XXXXX XXXXXX . Arctic Bioscience acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Arctic Bioscience founded? | Arctic Bioscience was founded in 2011. |
| Where is Arctic Bioscience headquartered? | Arctic Bioscience is headquartered in Norway. |
| How many employees does Arctic Bioscience have? | As of today, Arctic Bioscience has 25 employees. |
| Is Arctic Bioscience publicy listed? | Yes, Arctic Bioscience is a public company listed on OSL. |
| What is the stock symbol of Arctic Bioscience? | Arctic Bioscience trades under ABS ticker. |
| When did Arctic Bioscience go public? | Arctic Bioscience went public in 2021. |
| Who are competitors of Arctic Bioscience? | Similar companies to Arctic Bioscience include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Arctic Bioscience? | Arctic Bioscience's current market cap is $9.8M |
| What is the current revenue of Arctic Bioscience? | Arctic Bioscience's last 12 months revenue is $6.2M. |
| What is the current revenue growth of Arctic Bioscience? | Arctic Bioscience revenue growth (NTM/LTM) is 40%. |
| What is the current EV/Revenue multiple of Arctic Bioscience? | Current revenue multiple of Arctic Bioscience is 2.1x. |
| Is Arctic Bioscience profitable? | Yes, Arctic Bioscience is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Arctic Bioscience? | Arctic Bioscience's last 12 months EBITDA is -$1.9M. |
| What is Arctic Bioscience's EBITDA margin? | Arctic Bioscience's last 12 months EBITDA margin is -30%. |
| What is the current EV/EBITDA multiple of Arctic Bioscience? | Current EBITDA multiple of Arctic Bioscience is -6.8x. |
| What is the current FCF of Arctic Bioscience? | Arctic Bioscience's last 12 months FCF is -$5.3M. |
| What is Arctic Bioscience's FCF margin? | Arctic Bioscience's last 12 months FCF margin is -85%. |
| What is the current EV/FCF multiple of Arctic Bioscience? | Current FCF multiple of Arctic Bioscience is -2.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
